Biomarkers for cognitive impairment in Parkinson disease.
Cognitive impairment, including dementia, is commonly seen in those afflicted with Parkinson disease (PD), particularly at advanced disease stages. Pathologically, PD with dementia (PD-D) is most often associated with the presence of cortical Lewy bodies, as is the closely related dementia with Lewy bodies (DLB). Both PD-D and DLB are also frequently complicated by the presence of neurofibrillary tangles and amyloid plaques, features most often attributed to Alzheimer disease. Biomarkers are urgently needed to differentiate among these disease processes and predict dementia in PD as well as monitor responses of patients to new therapies. A few clinical assessments, along with structural and functional neuroimaging, have been utilized in the last few years with some success in this area. Additionally, a number of other strategies have been employed to identify biochemical/molecular biomarkers associated with cognitive impairment and dementia in PD, e.g. targeted analysis of candidate proteins known to be important to PD pathogenesis and progression in cerebrospinal fluid or blood. Finally, interesting results are emerging from preliminary studies with unbiased and high throughput genomic, proteomic and metabolomic techniques. The current findings and perspectives of applying these strategies and techniques are reviewed in this article, together with potential areas of advancement.
Shi
Min
M
Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA.
Huber
Bertrand R
BR
Zhang
Jing
J
D015415:Biomarkers / Q000032:analysis; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism*; D003704:Dementia / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism*; D003937:Diagnosis, Differential; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000378:metabolism*
D015415:Biomarkers